their first revenues from private sales happened in the last...

their first revenues from private sales happened in the last quarter. 3 sales all in New Zealand, which currently is the only place they can sell. 90k total revenue. This quarter if things go well and they get their last check box ticked they will be able to sell in the uk in 9 hospitals which effectively cover the whole UKs population. They should also this quarter, once again if they get the tick from TGA be able to sell in Australia. And thirdly due most likely early next quarter is the HDE approval in the US which will allow them to sell there too although only a limited number per year until they do another study which if they get the approval the FDA will help them put together and may help with funding. There are lots of other applications and things they are doing but that is the big 3 that people are looking for as they will control future revenue in the short term at least. On the negative side and why some long term holders aren’t happy is that the old team who got dropped last quarter seemed to drag their feet a bit and appeared to cause some unnecessary delays. The new team however has done all this before successfully in Sirtex and has made all the moves people on this forum have been complaining about for the last year in the first month or so of taking over. COVID also cost them as access to hospitals in the main area they were targeting first became impossible, but now with the rollout of the vaccine it should no longer be the progress killer it was. The only genuine real big risk I see here is if the approvals to sell get knocked back. But no risk no reward they say